

Pedmark (sodium thiosulfate injection)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Pedmark (sodium thiosulfate injection) for intravenous use

APPROVAL CRITERIA

Requests for Pedmark (sodium thiosulfate injection) may be approved if the following criteria are met:

- I. Individual has a diagnosis of localized, non-metastatic solid tumor; **AND**
- II. Individual is using to reduce the risk of ototoxicity associated with cisplatin; **AND**
- III. Pedmark will be administered starting 6 hours after completion of cisplatin infusion, OR for multiday cisplatin regimens, Pedmark will be administered 6 hours after each cisplatin infusion but at least 10 hours before the next cisplatin infusion; **AND**
- IV. Individual has a baseline serum sodium less than 145 mmol/L; **AND**
- V. Individual is 1 month of age or older;

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: April 5, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.